Abstract:
:The efficacy of an antiretroviral (ARV) treatment regimen depends on the activity of the regimen's individual ARV drugs and the number of HIV-1 mutations required for the development of resistance to each ARV - the genetic barrier to resistance. ARV resistance impairs the response to therapy in patients with transmitted resistance, unsuccessful initial ARV therapy and multiple virological failures. Genotypic resistance testing is used to identify transmitted drug resistance, provide insight into the reasons for virological failure in treated patients, and help guide second-line and salvage therapies. In patients with transmitted drug resistance, the virological response to a regimen selected on the basis of standard genotypic testing approaches the responses observed in patients with wild-type viruses. However, because such patients are at a higher risk of harbouring minority drug-resistant variants, initial ARV therapy in this population should contain a boosted protease inhibitor (PI) - the drug class with the highest genetic barrier to resistance. In patients receiving an initial ARV regimen with a high genetic barrier to resistance, the most common reasons for virological failure are nonadherence and, potentially, pharmacokinetic factors or minority transmitted drug-resistant variants. Among patients in whom first-line ARVs have failed, the patterns of drug-resistance mutations and cross-resistance are often predictable. However, the extent of drug resistance correlates with the duration of uncontrolled virological replication. Second-line therapy should include the continued use of a dual nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-containing backbone, together with a change in the non-NRTI component, most often to an ARV belonging to a new drug class. The number of available fully active ARVs is often diminished with each successive treatment failure. Therefore, a salvage regimen is likely to be more complicated in that it may require multiple ARVs with partial residual activity and compromised genetic barriers of resistance to attain complete virological suppression. A thorough examination of the patient's ARV history and prior resistance tests should be performed because genotypic and/or phenotypic susceptibility testing is often not sufficient to identify drug-resistant variants that emerged during past therapies and may still pose a threat to a new regimen. Phenotypic testing is also often helpful in this subset of patients. ARVs used for salvage therapy can be placed into the following hierarchy: (i) ARVs belonging to a previously unused drug class; (ii) ARVs belonging to a previously used drug class that maintain significant residual antiviral activity; (iii) NRTI combinations, as these often appear to retain in vivo virological activity, even in the presence of reduced in vitro NRTI susceptibility; and rarely (iv) ARVs associated with previous virological failure and drug resistance that appear to have possibly regained their activity as a result of viral reversion to wild type. Understanding the basic principles of HIV drug resistance is helpful in guiding individual clinical decisions and the development of ARV treatment guidelines.
journal_name
Drugsjournal_title
Drugsauthors
Tang MW,Shafer RWdoi
10.2165/11633630-000000000-00000subject
Has Abstractpub_date
2012-06-18 00:00:00pages
e1-25issue
9eissn
0012-6667issn
1179-1950pii
3journal_volume
72pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Alipogene tiparvovec (Glybera®; AMT-011, AAV1-LPL(S447X)) is an adeno-associated virus serotype 1-based gene therapy for adult patients with familial lipoprotein lipase (LPL) deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. It is administered as a one-time ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0339-9
更新日期:2015-02-01 00:00:00
abstract::The use of digitalis in congestive heart failure with normal sinus rhythm is still debated. While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data, with poorly documented clinical status and poor haemodynamic and exercise data, some patients did improve clinically when digitalis treatm...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199855060-00002
更新日期:1998-06-01 00:00:00
abstract::In a study of the effects of various NSAIDs on renal function in the elderly, indomethacin, tiaprofenic acid and sulindac were administered to patients ranging in age from 54 to 97 years for a period of 3 months. Indomethacin sustained release (25 mg tid) was administered to 66 patients, tiaprofenic acid (200 mg tid) ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800351-00022
更新日期:1988-01-01 00:00:00
abstract::The emergence of antibiotic resistance is primarily due to excessive and often unnecessary use of antibiotics in humans and animals. Risk factors for the spread of resistant bacteria in hospitals and the community can be summarised as over-crowding, lapses in hygiene or poor infection control practices. Increasing ant...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199855030-00001
更新日期:1998-03-01 00:00:00
abstract::The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-alpha -- infliximab, etanercept and adalimumab -- have consistently shown very good efficacy for...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868050-00003
更新日期:2008-01-01 00:00:00
abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0960-0
更新日期:2018-08-01 00:00:00
abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0258-9
更新日期:2014-08-01 00:00:00
abstract::Despite advances in the understanding of the mechanism of cerebral injury during focal ischaemia, the best treatment of cerebral ischaemia is still prevention. The pathophysiological mechanisms that contribute to cerebral ischaemia are discussed relative to the many therapeutic interventions that have been attempted. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198835040-00005
更新日期:1988-04-01 00:00:00
abstract::Purine nucleoside analogues are a new class of drugs with activity against nondividing lymphocytes; thus, they should play a major role in the treatment of low grade lymphoid malignancies. As these drugs are active against resting lymphocytes, harmful effects related to this action were expected and have been reported...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199400476-00009
更新日期:1994-01-01 00:00:00
abstract::The extra-oesophageal signs that are most commonly related to gastro-oesophageal reflux include chest pain, asthma, chronic cough, posterior laryngitis and dental erosions. It is characteristic to find in such patients a poor presence of symptoms and endoscopic and pH-metric findings that are common in typical reflux....
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565001-00010
更新日期:2005-01-01 00:00:00
abstract::Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation by decision makers and formulates a num...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11538120-000000000-00000
更新日期:2010-10-22 00:00:00
abstract::Administration of unopposed postmenopausal estrogen therapy protects against coronary heart disease (CHD) in women. This is mediated, in part, through beneficial effects on lipid and lipoprotein metabolism. Fewer data are available with regard to CHD risk reduction when a progesterone is required in addition to estrog...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199400472-00005
更新日期:1994-01-01 00:00:00
abstract::Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disease that ultimately leads to disability and functional decline. Because patients usually develop RA in mid-life, they may experience its consequences for 20-30 years or longer. Proinflammatory cytokines, notably interleukin (IL)-1 and tumour necro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464220-00001
更新日期:2004-01-01 00:00:00
abstract::The advent of thrombolytic therapy was a major advance in the treatment of ST-segment elevation myocardial infarction (STEMI). The administration of fibrinolytic reperfusion therapy can reduce mortality rates by as much as 30%, with the greatest benefit observed if therapy is administered soon after symptom onset. Out...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11317670-000000000-00000
更新日期:2009-10-01 00:00:00
abstract::Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11635960-000000000-00000
更新日期:2012-09-10 00:00:00
abstract::Vemurafenib is the first molecularly targeted therapy to be licensed in the US and Europe for treatment of advanced melanoma. Its mechanism of action involves selective inhibition of the mutated BRAF V600E kinase that leads to reduced signalling through the aberrant mitogen-activated protein kinase (MAPK) pathway. Its...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11640870-000000000-00000
更新日期:2012-12-03 00:00:00
abstract::Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. This review examines the...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161040-00004
更新日期:2001-01-01 00:00:00
abstract::Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363100-00004
更新日期:2003-01-01 00:00:00
abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-016-0634-8
更新日期:2016-09-01 00:00:00
abstract::Although the incidence of HIV-associated cryptococcosis has decreased in developed countries since the introduction of antiretroviral therapy, this disease continues to cause significant morbidity and mortality in sub-Saharan Africa among patients with AIDS. Important strides have been made in an attempt to decrease t...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0037-z
更新日期:2013-05-01 00:00:00
abstract::The concept of balanced analgesia was introduced to improve analgesic efficacy and reduce adverse effects. A large amount of clinical data has documented improved analgesia by combining different analgesics, but data on reducing adverse effects are inconclusive. Balanced analgesia should be used whenever possible, and...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958050-00002
更新日期:1999-11-01 00:00:00
abstract::Multiple sclerosis (MS) is thought to be a chronic inflammatory disorder of the CNS. The past decade has seen the introduction of the new immunomodulatory drugs, interferon (IFN)-beta and glatiramer acetate, that have considerably improved the therapeutic options for this often disabling disease. The efficacy of these...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363150-00001
更新日期:2003-01-01 00:00:00
abstract::Gastro-oesophageal reflux disease (GORD or GERD) is a very common disorder, and advancement in drug development over the years has markedly improved disease management. Proton pump inhibitors (PPIs) remain the mainstay of treatment for GERD due to their profound and consistent inhibitory effect on acid secretion. Howe...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11597300-000000000-00000
更新日期:2011-12-24 00:00:00
abstract::Amiodarone is a class III antiarrhythmic drug with sympatholytic properties, which prolongs the refractory period of all cardiac tissues, depresses sinus node automaticity and atrioventricular nodal conduction. It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracard...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199100412-00009
更新日期:1991-01-01 00:00:00
abstract::In this paper, several clinical problems associated with the diagnosis of hypertension are discussed. Blood pressure variability and reactivity are factors underlying the difficulties in the diagnosis of hypertension. These phenomena are interrelated and mixed. White coat hypertension (WCH), referring to the phenomeno...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199300462-00017
更新日期:1993-01-01 00:00:00
abstract::Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199500492-00012
更新日期:1995-01-01 00:00:00
abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856002-00004
更新日期:1998-01-01 00:00:00
abstract::Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist. Intravenous tocilizumab 8 mg/kg (and no less than 4.8 mg), in combination with methotrexate, is approved in the EU for the treatment of moderate to severe active rheumatoid arthriti...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200969050-00007
更新日期:2009-01-01 00:00:00
abstract::Despite remarkable advances in cardiovascular therapeutics, sudden cardiac death remains a significant problem. In this review, data from clinical trials and other studies on antiarrhythmic therapies have been evaluated in order to determine effective strategies for the prevention of sudden cardiac death in high risk ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199754020-00003
更新日期:1997-08-01 00:00:00
abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767001-00005
更新日期:2007-01-01 00:00:00